drugset
drugset / Trial / NCT02171793

Single Rising Peroral Doses of BI 1744 CL in Healthy Volunteers

NCT02171793 ↗

Phase 1 Completed 24 enrolled Boehringer Ingelheim
RandomizedParallel-groupSingle-blindTreatment

Summary

Study to investigate safety, tolerability, and pharmacokinetics of single rising peroral doses of BI 1744 CL.

Timeline

Start
2007-06
Primary completion
2007-07
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Olodaterol Small molecule 15 ug Oral
Subject Olodaterol Small molecule 30 ug Oral
Subject Olodaterol Small molecule 40 ug Oral

Indications

No indication recorded.